Bright side of the dark genome: antigens for next-gen cancer vaccines.

68 A subsequent phase II trial 69 in patients with resected stage IIb–IV melanoma compared adjuvant therapy with a personalized mRNA neoantigen vaccine plus anti-PD-1 versus anti-PD-1 alone and demonstrated a favorable trend toward improved recurrence-free survival (p=0.053), which led to the initiation of a phase III trial. 69 Vaccination both amplified pre-existing neoantigen-specific T-cell responses and elicited de novo responses to vaccine antigens, with expansion of both CD4 + and CD8 + T-cell populations undersc

also in 1,335 other papers